HOUSTON, June 20, 2019 /PRNewswire/ -- Marker
Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage
immuno-oncology company specializing in the development of
next-generation T cell-based immunotherapies for the treatment of
hematological malignancies and solid tumor indications,
today announced that updated clinical data from an
investigator-sponsored Phase 1/2 trial led by Baylor College of Medicine were selected for oral
presentation during a plenary session at the upcoming American
Association for Cancer Research's (AACR) Immune Cell Therapies for
Cancer: Successes and Challenges of CAR T Cells and Other Forms of
Adoptive Therapy conference. The data—which will also be presented
in a poster session—will be reviewed by Brandon G. Smaglo, M.D., FACP, Assistant
Professor, Medical Director of Hematology/Oncology at the Baylor
College of Medicine, Houston,
Texas.
Oral Presentation Details
Title: "Targeting
pancreatic cancer using nonengineered, multiantigen-specific T
cells (TACTOPS)"
Date: Saturday, July 20, 2019
Time (Plenary Session #1): 8:00 a.m.
- 10:00 a.m. PST
Location: Hyatt Regency, San
Francisco, CA
Poster Presentation Details
Title: "Targeting
pancreatic cancer using nonengineered, multiantigen-specific T
cells (TACTOPS)"
Date: Saturday, July 20, 2019
Time (Poster Session A): 12:30 p.m. – 2:30 p.m. PST
Location: Hyatt Regency, San
Francisco, CA
Investor Event
For those unable to attend the presentations at AACR, Marker will
host a live investor event following the conference on Monday, July 22nd at 1:30
p.m. PST in San Francisco
featuring Dr. Brandon Smaglo, as
well as Marker senior management. A live webcast of the investor
presentation will be available in the investors section
of the Company's website
at https://www.markertherapeutics.com/ and will be
available for replay following the event.
About Marker Therapeutics, Inc.
Marker Therapeutics,
Inc. is a clinical-stage immuno-oncology company specializing in
the development of next-generation T cell-based immunotherapies for
the treatment of hematological malignancies and solid tumor
indications. Marker's cell therapy technology is based on the
selective expansion of non-engineered, tumor-specific T cells that
recognize tumor associated antigens (i.e. tumor targets) and kill
tumor cells expressing those targets. This population of T cells is
designed to attack multiple tumor targets following infusion into
patients and to activate the patient's immune system to produce
broad spectrum anti-tumor activity. Because Marker does not
genetically engineer its T cells therapies, we believe that our
product candidates will be easier and less expensive to
manufacture, with reduced toxicities, compared to current
engineered CAR-T and TCR-based approaches, and may provide patients
with meaningful clinical benefit. As a result, Marker believes its
portfolio of T cell therapies has a compelling therapeutic product
profile, as compared to current gene-modified CAR-T and TCR-based
therapies.
Marker is also advancing a number of innovative peptide- and
gene-based immuno-therapeutics for the treatment of metastatic
solid tumors, including the Folate Receptor Alpha program (TPIV200)
for breast and ovarian cancers and the HER2/neu program
(TPIV100/110) for breast cancer, currently in Phase 2 clinical
trials.
For additional information, please call toll free at (904)
862-6490 or visit: https://www.markertherapeutics.com/
To receive future press releases via email, please
visit: https://markertherapeutics.com/email-alerts/
Follow us on Twitter @MRKRTherapeutic, or follow us
on Facebook.
Forward-Looking Statement Disclaimer
This release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Statements in this news release concerning the
Company's expectations, plans, business outlook or future
performance, and any other statements concerning assumptions made
or expectations as to any future events, conditions, performance or
other matters, are "forward-looking statements." Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things: our research and development activities
relating to our non-engineered multi-tumor antigen specific T cell
therapies; our TPIV200 and TPIV100/110 programs; the effectiveness
of these programs or the possible range of application and
potential curative effects and safety in the treatment of diseases;
and, the timing and success of our clinical trials, as well as
clinical trials conducted by our collaborators. Forward-looking
statements are by their nature subject to risks, uncertainties and
other factors which could cause actual results to differ materially
from those stated in such statements. Such risks, uncertainties and
factors include, but are not limited to the risks set forth in the
Company's most recent Form 10-K, 10-Q and other SEC filings which
are available through EDGAR at www.sec.gov. The Company assumes no
obligation to update our forward-looking statements whether as a
result of new information, future events or otherwise, after the
date of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-to-report-updated-results-from-phase-12-trial-with-multitaa-therapy-in-patients-with-pancreatic-adenocarcinoma-300871612.html
SOURCE Marker Therapeutics, Inc.